- 'Cancer of Fraud' Permeates Health Care System: Critics
- For Many in US, It Will Be a Scaled-Down Holiday Season
- Judge Erases Couple's $525,000 Mortgage Payment
- Where Do Pardoned Turkeys Go?
- Foreign Demand Boosts US 7-Year Treasury Sale
- Google CEO Schmidt Makes Secret Visit to Iraq
- New-Home Sales Jump to Highest Level in Over a Year
- Consumers Catching the Holiday Spirit
- Jobless Claims Below 500,000, Durable Orders Slip
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- S&P Stocks Trading at New 52-Week Highs
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
MOST SHARED
- Ritz-Carlton ?Struggling? in the US: President
- Garlic Price Rises Surpass Gold, Stocks in China
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- S&P Stocks Trading at New 52-Week Highs
- Oil Price to Average $75.40 in 2010: Poll
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Consumer Mood Improves, But Anxiety Over Personal Finances
- Jobless Claims Below 500,000, Durable Orders Slip
- Foreign Demand Boosts US 7-Year Treasury Sale
- Mortgage Demand Slips as Rates Hold Near Lows
Text Size 
Pfizer's acquisition of Wyeth will add to the pharmaceutical giant's diversity, which over time will help boost the company's stock, CEO Jeff Kindler told CNBC Tuesday.
"Ultimately, the way we increase the stock is by improving shareholder value in the long run," Kindler said. "Our prospects are very strong."
Pfizer [PFE
Loading...
()
] plans to cut about $4 billion in annual expenses after the acquisition is complete, and it will eliminate 15 percent of the companies' combined employees, he said.
Kindler added that management will discuss the future of the company's dividend in December, after cutting it in half to 64 cents earlier this year.
"We'll consider the importance of the dividend to our shareholders, which we understand very much," he said, "as well as all considerations about the best use of our capital for our shareholders."
On Tuesday, Pfizer reported third-quarter earnings that beat Wall Street's profit expectations as cost-cutting outweighed a decline in sales.
Also on CNBC.com:
Print
Email
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
- How can you get out of debt and back on the road to recovery? Follow these ten steps.
Data is a real-time snapshot *Data is delayed at least 15 minutes